| Item Type | Name |
|
Concept
|
Antigens, Neoplasm
|
|
Concept
|
Antigens
|
|
Concept
|
Antigens, Differentiation
|
|
Concept
|
Antigens, Surface
|
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
|
Concept
|
Histocompatibility Antigens Class II
|
|
Concept
|
Histocompatibility Antigens
|
|
Concept
|
H-2 Antigens
|
|
Concept
|
HLA-A Antigens
|
|
Concept
|
CD28 Antigens
|
|
Concept
|
Histocompatibility Antigens Class I
|
|
Concept
|
CD8 Antigens
|
|
Concept
|
Antigens, CD
|
|
Concept
|
CD40 Antigens
|
|
Concept
|
Thy-1 Antigens
|
|
Concept
|
CD2 Antigens
|
|
Concept
|
Leukocyte Common Antigens
|
|
Concept
|
CD4 Antigens
|
|
Concept
|
CD5 Antigens
|
|
Academic Article
|
Differential regulation of murine T lymphocyte subsets.
|
|
Academic Article
|
Differential function of intestinal intraepithelial lymphocyte subsets.
|
|
Academic Article
|
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
|
|
Academic Article
|
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
|
|
Academic Article
|
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones.
|
|
Academic Article
|
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
|
|
Academic Article
|
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
|
|
Academic Article
|
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
|
|
Academic Article
|
Blocked Ras activation in anergic CD4+ T cells.
|
|
Academic Article
|
Rational development of tumour antigen-specific immunization in melanoma.
|
|
Academic Article
|
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity.
|
|
Academic Article
|
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.
|
|
Academic Article
|
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.
|
|
Academic Article
|
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
|
|
Academic Article
|
Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.
|
|
Academic Article
|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
|
|
Academic Article
|
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.
|
|
Academic Article
|
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
|
|
Academic Article
|
Transplantation and the CD28/CTLA4/B7 pathway.
|
|
Academic Article
|
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
|
|
Academic Article
|
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
|
|
Academic Article
|
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
|
|
Academic Article
|
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
|
|
Academic Article
|
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xL.
|
|
Academic Article
|
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.
|
|
Academic Article
|
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
|
|
Academic Article
|
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
|
|
Academic Article
|
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
|
|
Academic Article
|
Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation.
|
|
Academic Article
|
CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.
|
|
Academic Article
|
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
|
|
Academic Article
|
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines.
|
|
Academic Article
|
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.
|
|
Academic Article
|
Update on vaccines for solid tumors.
|
|
Academic Article
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
|
|
Academic Article
|
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones.
|
|
Academic Article
|
Immune suppression in the tumor microenvironment.
|
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
|
Academic Article
|
Molecular regulation of T-cell anergy.
|
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
|
Academic Article
|
Negative regulation of T-cell function by PD-1.
|
|
Academic Article
|
Peripheral survival of naïve CD8+ T cells.
|
|
Academic Article
|
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
|
|
Academic Article
|
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
|
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
|
Academic Article
|
Phenotypic and functional analysis of murine CD3+,CD4-,CD8- TCR-gamma delta-expressing peripheral T cells.
|
|
Academic Article
|
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
|
|
Academic Article
|
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
|
|
Academic Article
|
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.
|
|
Academic Article
|
Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone.
|
|
Academic Article
|
Regulation of T-cell activation: differences among T-cell subsets.
|
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
|
Academic Article
|
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.
|
|
Academic Article
|
Differential requirement for protein tyrosine kinase Fyn in the functional activation of antigen-specific T lymphocyte clones through the TCR or Thy-1.
|
|
Academic Article
|
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
|
|
Academic Article
|
From defined human tumor antigens to effective immunization?
|
|
Academic Article
|
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
|
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
|
Academic Article
|
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
|
|
Academic Article
|
Expression and function of CTLA-4 in Th1 and Th2 cells.
|
|
Academic Article
|
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
|
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
|
Academic Article
|
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
|
|
Academic Article
|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
|
|
Academic Article
|
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
|
|
Academic Article
|
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
|
|
Academic Article
|
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
|
|
Academic Article
|
Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.
|
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
|
Academic Article
|
The composition of the microbiota modulates allograft rejection.
|
|
Academic Article
|
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
|
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
|
Academic Article
|
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
|
|
Academic Article
|
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
|
|
Academic Article
|
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
|
|
Academic Article
|
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
|